Trophogen, Inc. is a biotechnology company founded in 2001 with series A funding from Toucan Capital, focusing on the development of high affinity glycoprotein hormone and related growth factor analogs for human and animal infertility as well as targeted therapy and imaging of thyroid, ovarian, breast, prostate and testicular cancers.
